Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6030969 | 0.97 | ELANE (0.44) | ELANEMEN1KMT2AMAPTF2 | |
| SCHEMBL6030401 | 0.97 | ELANE (0.44) | ELANEMEN1KMT2AMAPTF2 | |
| SCHEMBL1628043 | 0.97 | ELANE (0.44) | ELANEMEN1KMT2AMAPTF2 | |
| SCHEMBL6030763 | 0.97 | ELANE (0.44) | ELANEMEN1KMT2AMAPTF2 | |
| SCHEMBL1626751 | 0.97 | ELANE (0.44) | ELANEMEN1KMT2AMAPTF2 | |
| SCHEMBL6029722 | 0.91 | ELANE (0.41) | ELANEMEN1KMT2AMAPTF2 | |
| SCHEMBL6031265 | 0.90 | ELANE (0.46) | ELANEMEN1KMT2AMAPTF2 | |
| SCHEMBL6030321 | 0.89 | ELANE (0.41) | ELANEMEN1KMT2AMAPTF2 | |
| SCHEMBL6030440 | 0.89 | MAPT (0.42) | ELANEMEN1KMT2AMAPTF2 | |
| SCHEMBL6030090 | 0.89 | MAPT (0.42) | ELANEMEN1KMT2AMAPTF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4668536-B2 | — | — | 2011-04-13 | — | — | JP | claimed |
| US-7064122-B2 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2006-06-20 | — | — | US | claimed |
| EP-1467978-A4 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-11-02 | — | — | EP | claimed |
| JP-2005518383-A | — | — | 2005-06-23 | — | — | JP | claimed |
| EP-1467978-A1 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | claimed |
| US-20030195199-A1 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-10-16 | — | — | US | claimed |
| WO-2003053944-A1 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | claimed |
| US-7064122-B2 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1467978-A4 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1467978-A1 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030195199-A1 | Pancreatic lipase inhibitor compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003053944-A1 | PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195199-A1 | Pancreatic lipase inhibitor compounds, their synthesis and use | PNLIP, LIPC, CEL | ELANE 692/4885MEN1 4799/4885KMT2A 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.